Transrectal ultrasound for monitoring murine orthotopic prostate tumor

Nobuyuki Kusaka, Yasutomo Nasu, Ryoji Arata, Takashi Saika, Tomoyasu Tsushima, Robert Kraaij, Chris H. Bangma, Hiromi Kumon

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

BACKGROUND. The mouse orthotopic prostate tumor model has been recognized as an ideal preclinical animal model simulating the anatomical and biological milieu of the prostate. In comparison with the subcutaneous tumor model, the only disadvantage of this model is the difficulty of chronological tumor growth monitoring. We have applied recent endoluminal ultrasound technology, transrectal ultrasonography (TRUS), to the monitoring of mouse orthotopic prostate tumors. METHODS. A 6 Fr. 20 MHz catheter-based radial scan probe was used and TRUS was performed without any prior preparation including anesthesia. Orthotopic tumors were initiated by inoculation of 5000 RM-9 cells into the dorsal prostate of 12-week-old C57BL/6 male mice. The tumor growth was monitored by TRUS from day 3 to day 21. In addition, TRUS was performed to detect tumor growth suppression after intraperitoneal administration of cis-diamminedichloroplatinum (CDDP). RESULTS. By ultrasound, tumors became detectable 7 days after tumor cell inoculation. TRUS images were clear and parallel to actual tumor growth. The tumor volume (X) calculated by TRUS correlated significantly with the actual tumor weight (Y) measured at autopsy; Y = 101.653 + 1.174X (R = 0.930, P <0.001). Similarly, tumor growth suppression induced by CDDP was clearly detected by TRUS with reasonable accuracy. CONCLUSIONS. A high resolution TRUS allows simple and reliable monitoring of in situ tumor growth and growth suppression, making the mouse orthotopic prostate tumor model more efficient.

Original languageEnglish
Pages (from-to)118-124
Number of pages7
JournalProstate
Volume47
Issue number2
DOIs
Publication statusPublished - May 1 2001

Fingerprint

Prostate
Ultrasonography
Neoplasms
Growth
Tumor Burden
Cisplatin
Autopsy
Catheters
Anesthesia
Animal Models
Technology

Keywords

  • Animal model
  • Orthotopic implantation
  • Prostate cancer
  • Ultrasonography

ASJC Scopus subject areas

  • Urology

Cite this

Kusaka, N., Nasu, Y., Arata, R., Saika, T., Tsushima, T., Kraaij, R., ... Kumon, H. (2001). Transrectal ultrasound for monitoring murine orthotopic prostate tumor. Prostate, 47(2), 118-124. https://doi.org/10.1002/pros.1054

Transrectal ultrasound for monitoring murine orthotopic prostate tumor. / Kusaka, Nobuyuki; Nasu, Yasutomo; Arata, Ryoji; Saika, Takashi; Tsushima, Tomoyasu; Kraaij, Robert; Bangma, Chris H.; Kumon, Hiromi.

In: Prostate, Vol. 47, No. 2, 01.05.2001, p. 118-124.

Research output: Contribution to journalArticle

Kusaka, N, Nasu, Y, Arata, R, Saika, T, Tsushima, T, Kraaij, R, Bangma, CH & Kumon, H 2001, 'Transrectal ultrasound for monitoring murine orthotopic prostate tumor', Prostate, vol. 47, no. 2, pp. 118-124. https://doi.org/10.1002/pros.1054
Kusaka N, Nasu Y, Arata R, Saika T, Tsushima T, Kraaij R et al. Transrectal ultrasound for monitoring murine orthotopic prostate tumor. Prostate. 2001 May 1;47(2):118-124. https://doi.org/10.1002/pros.1054
Kusaka, Nobuyuki ; Nasu, Yasutomo ; Arata, Ryoji ; Saika, Takashi ; Tsushima, Tomoyasu ; Kraaij, Robert ; Bangma, Chris H. ; Kumon, Hiromi. / Transrectal ultrasound for monitoring murine orthotopic prostate tumor. In: Prostate. 2001 ; Vol. 47, No. 2. pp. 118-124.
@article{e037a644737c418da1d0af211f7b4be9,
title = "Transrectal ultrasound for monitoring murine orthotopic prostate tumor",
abstract = "BACKGROUND. The mouse orthotopic prostate tumor model has been recognized as an ideal preclinical animal model simulating the anatomical and biological milieu of the prostate. In comparison with the subcutaneous tumor model, the only disadvantage of this model is the difficulty of chronological tumor growth monitoring. We have applied recent endoluminal ultrasound technology, transrectal ultrasonography (TRUS), to the monitoring of mouse orthotopic prostate tumors. METHODS. A 6 Fr. 20 MHz catheter-based radial scan probe was used and TRUS was performed without any prior preparation including anesthesia. Orthotopic tumors were initiated by inoculation of 5000 RM-9 cells into the dorsal prostate of 12-week-old C57BL/6 male mice. The tumor growth was monitored by TRUS from day 3 to day 21. In addition, TRUS was performed to detect tumor growth suppression after intraperitoneal administration of cis-diamminedichloroplatinum (CDDP). RESULTS. By ultrasound, tumors became detectable 7 days after tumor cell inoculation. TRUS images were clear and parallel to actual tumor growth. The tumor volume (X) calculated by TRUS correlated significantly with the actual tumor weight (Y) measured at autopsy; Y = 101.653 + 1.174X (R = 0.930, P <0.001). Similarly, tumor growth suppression induced by CDDP was clearly detected by TRUS with reasonable accuracy. CONCLUSIONS. A high resolution TRUS allows simple and reliable monitoring of in situ tumor growth and growth suppression, making the mouse orthotopic prostate tumor model more efficient.",
keywords = "Animal model, Orthotopic implantation, Prostate cancer, Ultrasonography",
author = "Nobuyuki Kusaka and Yasutomo Nasu and Ryoji Arata and Takashi Saika and Tomoyasu Tsushima and Robert Kraaij and Bangma, {Chris H.} and Hiromi Kumon",
year = "2001",
month = "5",
day = "1",
doi = "10.1002/pros.1054",
language = "English",
volume = "47",
pages = "118--124",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Transrectal ultrasound for monitoring murine orthotopic prostate tumor

AU - Kusaka, Nobuyuki

AU - Nasu, Yasutomo

AU - Arata, Ryoji

AU - Saika, Takashi

AU - Tsushima, Tomoyasu

AU - Kraaij, Robert

AU - Bangma, Chris H.

AU - Kumon, Hiromi

PY - 2001/5/1

Y1 - 2001/5/1

N2 - BACKGROUND. The mouse orthotopic prostate tumor model has been recognized as an ideal preclinical animal model simulating the anatomical and biological milieu of the prostate. In comparison with the subcutaneous tumor model, the only disadvantage of this model is the difficulty of chronological tumor growth monitoring. We have applied recent endoluminal ultrasound technology, transrectal ultrasonography (TRUS), to the monitoring of mouse orthotopic prostate tumors. METHODS. A 6 Fr. 20 MHz catheter-based radial scan probe was used and TRUS was performed without any prior preparation including anesthesia. Orthotopic tumors were initiated by inoculation of 5000 RM-9 cells into the dorsal prostate of 12-week-old C57BL/6 male mice. The tumor growth was monitored by TRUS from day 3 to day 21. In addition, TRUS was performed to detect tumor growth suppression after intraperitoneal administration of cis-diamminedichloroplatinum (CDDP). RESULTS. By ultrasound, tumors became detectable 7 days after tumor cell inoculation. TRUS images were clear and parallel to actual tumor growth. The tumor volume (X) calculated by TRUS correlated significantly with the actual tumor weight (Y) measured at autopsy; Y = 101.653 + 1.174X (R = 0.930, P <0.001). Similarly, tumor growth suppression induced by CDDP was clearly detected by TRUS with reasonable accuracy. CONCLUSIONS. A high resolution TRUS allows simple and reliable monitoring of in situ tumor growth and growth suppression, making the mouse orthotopic prostate tumor model more efficient.

AB - BACKGROUND. The mouse orthotopic prostate tumor model has been recognized as an ideal preclinical animal model simulating the anatomical and biological milieu of the prostate. In comparison with the subcutaneous tumor model, the only disadvantage of this model is the difficulty of chronological tumor growth monitoring. We have applied recent endoluminal ultrasound technology, transrectal ultrasonography (TRUS), to the monitoring of mouse orthotopic prostate tumors. METHODS. A 6 Fr. 20 MHz catheter-based radial scan probe was used and TRUS was performed without any prior preparation including anesthesia. Orthotopic tumors were initiated by inoculation of 5000 RM-9 cells into the dorsal prostate of 12-week-old C57BL/6 male mice. The tumor growth was monitored by TRUS from day 3 to day 21. In addition, TRUS was performed to detect tumor growth suppression after intraperitoneal administration of cis-diamminedichloroplatinum (CDDP). RESULTS. By ultrasound, tumors became detectable 7 days after tumor cell inoculation. TRUS images were clear and parallel to actual tumor growth. The tumor volume (X) calculated by TRUS correlated significantly with the actual tumor weight (Y) measured at autopsy; Y = 101.653 + 1.174X (R = 0.930, P <0.001). Similarly, tumor growth suppression induced by CDDP was clearly detected by TRUS with reasonable accuracy. CONCLUSIONS. A high resolution TRUS allows simple and reliable monitoring of in situ tumor growth and growth suppression, making the mouse orthotopic prostate tumor model more efficient.

KW - Animal model

KW - Orthotopic implantation

KW - Prostate cancer

KW - Ultrasonography

UR - http://www.scopus.com/inward/record.url?scp=0035341595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035341595&partnerID=8YFLogxK

U2 - 10.1002/pros.1054

DO - 10.1002/pros.1054

M3 - Article

C2 - 11340634

AN - SCOPUS:0035341595

VL - 47

SP - 118

EP - 124

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 2

ER -